Skip to main content

Table 1 Baseline demographics and disease characteristics in the intent-to-treat population

From: Phase II study of R–CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma: consortium for improving survival of lymphoma (CISL) study

Characteristics Number of cases (%)
Age
 Median, years (range) 54 (33–77)
  < 60 29 (64.4)
  ≥ 60 16 (35.6)
Sex
 Male 32 (71)
 Female 13 (29)
ECOG performance score
 0–1 43 (96)
 2 2 (4)
Ann Arbor stage at diagnosis
 III 11 (24)
 IV 34 (76)
LDH
 Within normal range 35 (78)
 Elevated 7 (16)
 Unchecked 3 (7)
B symptomsa
 Absent 38 (84)
 Present 7 (16)
BM involvement
 Absent 34 (76)
 Present 11 (24)
Histology
 Nodal MZL 15 (33)
 MZL of MALT-type 30 (67)
 Lung 8 (18)
 Ocular and adnexa 6 (13)
 Stomach 4 (9)
 Bone 2 (4)
 Nasopharynx 2 (4)
 Multiple MALT sites 3 (7)
 Othersb 5 (11)
IPI score
 1 13 (29)
 2 21 (47)
 3 9 (20)
 4 2 (4)
Response to prior R–CVP
 CR 20 (44)
 PR 22 (49)
 SD 3 (7)
No. first line R–CVP (6 cycles) 10 (22)
Treatment cycles (8 cycles) 35 (78)
  1. Values are expressed as n (%) unless indicated otherwise
  2. BM bone marrow, CR complete response, ECOG Eastern Clinical Oncology Group, IPI International Prognostic Index, LDH lactate dehydrogenase, MALT mucosa-associated lymphoid tissue, MZL marginal zone B-cell lymphoma, PR partial response, RCVP rituximab cyclophosphamide vincristine prednisolone, SD stable disease
  3. aFever, night sweats, and/or weight loss
  4. bOne case each in the kidney, liver, nasal cavity, subcutaneous tissue, and small intestine